Hara Makoto, Ariño Helena, Petit-Pedrol Mar, Sabater Lidia, Titulaer Maarten J, Martinez-Hernandez Eugenia, Schreurs Marco W J, Rosenfeld Myrna R, Graus Francesc, Dalmau Josep
From the Clinical and Experimental Neuroimmunology Program (M.H., H.A., M.P.-P., L.S., E.M.-H., M.R.R., F.G., J.D.), August Pi Sunyer Biomedical Research Institute, Hospital Clínic, University of Barcelona, Spain; Division of Neurology (M.H.), Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Biomedical Research Networking Centre for Rare Diseases (H.A., J.D., M.P.-P., L.S., E.M.-H., M.R.R.), Valencia, Spain; Departments of Neurology (M.J.T.) and Immunology (M.W.J.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Department of Neurology (M.R.R., J.D.), University of Pennsylvania, Philadelphia; and Catalan Institution for Research and Advanced Studies (J.D.), Barcelona, Spain.
Neurology. 2017 Apr 4;88(14):1340-1348. doi: 10.1212/WNL.0000000000003796. Epub 2017 Mar 3.
To report the main syndrome of dipeptidyl-peptidase-like protein 6 (DPPX) antibody-associated encephalitis, immunoglobulin G (IgG) subclass, and the antibody effects on DPPX/Kv4.2 potassium channels.
A retrospective analysis of new patients and cases reported since 2013 was performed. IgG subclass and effects of antibodies on cultured neurons were determined with described techniques.
Nine new patients were identified (median age 57 years, range 36-69 years). All developed severe prodromal weight loss or diarrhea followed by cognitive dysfunction (9), memory deficits (5), CNS hyperexcitability (8; hyperekplexia, myoclonus, tremor, or seizures), or brainstem or cerebellar dysfunction (7). The peak of the disease was reached 8 months (range 1-54 months) after onset. All patients had both IgG4 and IgG1 DPPX antibodies. In cultured neurons, the antibodies caused a decrease of DPPX clusters and Kv4.2 protein that was reversible on removal of the antibodies. Considering the current series and previously reported cases (total 39), 67% developed the triad: weight loss (median 20 kg; range 8-53 kg)/gastrointestinal symptoms, cognitive-mental dysfunction, and CNS hyperexcitability. Outcome was available from 35 patients (8 not treated with immunotherapy): 60% had substantial or moderate improvement, 23% had no improvement (most of them not treated), and 17% died. Relapses occurred in 8 of 35 patients (23%) and were responsive to immunotherapy.
DPPX antibodies are predominantly IgG1 and IgG4 and associate with cognitive-mental deficits and symptoms of CNS hyperexcitability that are usually preceded by diarrhea, other gastrointestinal symptoms, and weight loss. The disorder is responsive to immunotherapy, and this is supported by the reversibility of the antibody effects in cultured neurons.
报告二肽基肽酶样蛋白6(DPPX)抗体相关脑炎的主要综合征、免疫球蛋白G(IgG)亚类以及抗体对DPPX/Kv4.2钾通道的影响。
对2013年以来报告的新患者和病例进行回顾性分析。采用所述技术测定IgG亚类以及抗体对培养神经元的影响。
确定了9例新患者(中位年龄57岁,范围36 - 69岁)。所有患者均先出现严重的前驱性体重减轻或腹泻,随后出现认知功能障碍(9例)、记忆缺陷(5例)、中枢神经系统(CNS)兴奋性增高(8例;惊跳反射亢进、肌阵挛、震颤或癫痫发作)或脑干或小脑功能障碍(7例)。发病后8个月(范围1 - 54个月)达到疾病高峰。所有患者均有IgG4和IgG1 DPPX抗体。在培养神经元中,抗体导致DPPX簇和Kv4.2蛋白减少,去除抗体后这种减少是可逆的。综合当前系列病例和先前报告的病例(共39例),67%的患者出现三联征:体重减轻(中位20 kg;范围8 - 53 kg)/胃肠道症状、认知 - 精神功能障碍和CNS兴奋性增高。35例患者(8例未接受免疫治疗)有预后数据:60%有显著或中度改善,23%无改善(其中大多数未接受治疗),17%死亡。35例患者中有8例(23%)复发,对免疫治疗有反应。
DPPX抗体主要为IgG1和IgG4,与认知 - 精神缺陷以及CNS兴奋性增高症状相关,这些症状通常先于腹泻、其他胃肠道症状和体重减轻出现。该疾病对免疫治疗有反应,培养神经元中抗体作用的可逆性支持了这一点。